P&G Pharmaceuticals - Trader Retailers/Wholesalers: Returned Goods Policy

United States

P&G Network Search

Pharmaceuticals:
US Products

Consumers:

Health Care Professionals:

FDA APPROVES NEW ONCE-A-MONTH DOSE OF ACTONEL FOR POSTMENOPAUSAL OSTEOPOROSIS

CINCINNATI, Bridgewater, NJ, April 24, 2008 — The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel� (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
More:

PROCTER & GAMBLE PHARMACEUTICALS RETURNED GOODS POLICY

This page applies to products at licensed retail/wholesale trade outlets, not consumers or healthcare professionals.

At P&G Pharmaceuticals, we value our retailers and wholesaler�s business and our relationship with them. To facilitate details of the process to return goods, we have implemented a Return Goods Policy. Click below for a detailed set of guidelines.

Read the Return Goods Policy




	©2008 Procter & Gamble. All claims valid only in the U.S. Legal Information Privacy Statement P&G Links